A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M in Healthy UK Adults
Key facts
- Who runs it
- University of Oxford
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Early phase 1
- People taking part
- 36 people, planned
- Started
- 13 Jan 2023
- Ended
- 31 Mar 2026
- Type of study
- Interventional, 4 groups
- Treatments tested
- Matrix M with R78C and/or RH5.1
- Record updated
- 1 April 2025
Who can take part
- Age
- 18 years to 45 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 30 criteriaShow less
Who can take part
- The volunteer must satisfy all the following criteria to be eligible for the study:
- Healthy adult aged 18 to 45 years
- Able and willing (in the Investigator's opinion) to comply with all study requirements
- Willing to allow the Investigators to discuss the volunteer's medical history with their GP
- Participants of childbearing potential only: must practice continuous effective contraception until 3 months after the final study vaccination (see section 9.10)
- Agreement to refrain from blood donation for the duration of the study
- Able and willing to provide written informed consent to participate in the trial
Who cannot take part
- History of clinical malaria (any species) or previous participation in any malaria vaccine trial or controlled human malaria infection trial
- Receipt of any vaccine in the 30 days preceding enrolment, or planned receipt of any other vaccine within 30 days following each study vaccination, with the exception of COVID-19 vaccines, which should not be received between 14 days before to 7 days after any study vaccination
- Receipt of an investigational product in the 30 days preceding enrolment, or planned receipt during the study period
- Concurrent involvement in another clinical trial involving an investigational product or planned involvement during the study period
- Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data, as assessed by the Investigator
- Suspected or known injecting drug use in the 5 years preceding enrolment
- Seropositive for hepatitis C virus (antibodies to HCV) at screening (unless volunteer has taken part in a prior hepatitis C vaccine study with confirmed negative HCV antibodies prior to participation in that study, and negative HCV ribonucleic acid (RNA) PCR at screening for this study)
- Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed)
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine
- Any history of anaphylaxis in reaction to vaccinations
- History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)
- History of serious psychiatric condition that may affect participation in the study
- Any other serious chronic illness requiring hospital specialist supervision
- Any other significant disease, disorder, or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data
- Hepatitis B surface antigen (HBsAg) detected in serum
- The volunteer may not enter the study if any of the following apply:
- Travel to a clearly malaria endemic locality during the study period or within the preceding six months
- Use of immunoglobulins or blood products (e.g. blood transfusion) in the last three months
- Pregnancy, lactation or intention to become pregnant during the study
- Suspected or known current alcohol misuse as defined by an alcohol intake of greater than 25 standard UK units every week
- Volunteers unable to be closely followed for social, geographic or psychological reasons
- Any clinically significant abnormal finding on biochemistry or haematology blood tests, urinalysis or clinical examination. In the event of abnormal test results, confirmatory repeat tests will be requested
- Inability of the study team to contact the volunteer's GP to confirm medical history and safety to participate
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is an open-label, single-centre Phase I P. falciparum blood-stage vaccine trial to assess the safety and immunogenicity and efficacy of the candidate malaria vaccines R78C and RH5.1 formulated in adjuvant Matrix-M
The 4 groups in the trial
- Group 1Treatment being tested
8+1 volunteers receiving three doses of 10 µg R78C with 50 µg of Matrix-M on days 0, 28 and 182 via intramuscular (IM) injection in the deltoid region of the non-dominant arm
Treatment: Matrix M with R78C and/or RH5.1
- Group 2Treatment being tested
8+1 volunteers receiving three doses of 10 µg R78C + 10 µg RH5.1 with 50 µg of Matrix-M on days 0, 28 and 182 via intramuscular (IM) injection in the deltoid region of the non-dominant arm
Treatment: Matrix M with R78C and/or RH5.1
- Group 3Treatment being tested
8+1 volunteers receiving three doses of 10 µg RH5.1 with 50 µg of Matrix-M on days 0, 28 and 56 via intramuscular (IM) injection in the deltoid region of the non-dominant arm
Treatment: Matrix M with R78C and/or RH5.1
- Group 4Treatment being tested
8+1 volunteers receiving two doses of 10 µg R78C + 10 µg RH5.1 with 50 µg of Matrix-M on days 0, 28, one dose of 10 µg R78C with 50 µg of Matrix-M on day 182 and one dose of 10 µg RH5.1 with 50 µg of Matrix-M on day 210, all administered via intramuscular (IM) injection in the deltoid region of the non-dominant arm
Treatment: Matrix M with R78C and/or RH5.1
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M, Both Alone and in Combination, in Healthy UK Adults
- Record updated
- 1 April 2025